Table 2

Incidence rates and 95% CIs, observation time, and number of events according to exposure status

Number of eventsObservation time (person years)Incidence rate per 100 person years (95% CI)
Non-exposed164.9427.167.5152.30 (2.29 to 2.31)
Nitrates (days)
 0–14912.6903.38 (2.75 to 4.15)
 15–30622.7362.27 (1.77 to 2.91)
 31–902747.8193.50 (3.11 to 3.94)
 91–1802948.9733.27 (2.92 to 3.67)
 >1804.155120.2383.46 (3.35 to 3.56)
Digoxin (days)
 0–141563.7394.17 (3.57 to 4.88)
 15–301884.1064.58 (3.97 to 5.28)
 31–9049512.5833.93 (3.08 to 3.67)
 91–18050515.0133.36 (3.08 to 3.67)
 >1805.792189.0663.06 (2.98 to 3.14)
Thiazides (days)
 0–1444612.5183.56 (3.25 to 3.91)
 15–3051813.4143.86 (3.54 to 4.21)
 31–901.50244.9583.34 (3.18 to 3.51)
 91–1801.27646.3352.75 (2.61 to 2.91)
 >18018.057687.4562.63 (2.59 to 2.67)
ACE inhibitors (days)
 0–1427311.8212.31 (2.05 to 2.60)
 15–3033013.0922.52 (2.26 to 2.81)
 31–9098041.4472.36 (2.22 to 2.52)
 91–1801.12449.9152.25 (2.12 to 2.39)
 >18015.910640.0662.49 (2.45 to 2.52)
Loop diuretics (days)
 0–1461511.5905.31 (4.90 to 5.74)
 15–3057011.8834.80 (4.42 to 5.21)
 31–901.32930.2814.39 (4.16 to 4.63)
 91–1801.58436.1894.38 (4.17 to 4.60)
 >18018.846475.4563.96 (3.91 to 4.02)
Calcium antagonists (days)
 0–1424910.5322.36 (2.09 to 2.68)
 15–3031511.9002.64 (2.37 to 2.96)
 31–9092639.8132.33 (2.18 to 2.48)
 91–1801.11150.4282.20 (2.08 to 2.34)
 >18016.691663.1962.52 (2.48 to 2.56)
β-Blockers (days)
 0–1426010.8432.39 (2.12 to 2.71)
 15–3030411.9322.55 (2.28 to 2.85)
 31–9097437.5622.59 (2.44 to 2.76)
 91–1801.20847.6722.53 (2.40 to 2.68)
 >18019.194761.9362.52 (2.48 to 2.56)
Statins (days)
 0–1422412.3421.81 (1.59 to 2.07)
 15–3026714.0331.90 (1.69 to 2.15)
 31–9087748.7451.80 (1.68 to 1.92)
 91–1801.16862.6081.87 (1.76 to 1.98)
 >18022.8581.100.1652.08 (2.05 to 2.10)
Angiotensin receptor antagonists (days)
 0–141315.8972.22 (1.87 to 2.64)
 15–301296.1852.09 (1.75 to 2.48)
 31–9037919.9381.90 (1.72 to 2.10)
 91–18055626.1302.12 (1.96 to 2.31)
 >1807.636333.9442.29 (2.24 to 2.34)